200 related articles for article (PubMed ID: 31818947)
1. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.
Jacków J; Guo Z; Hansen C; Abaci HE; Doucet YS; Shin JU; Hayashi R; DeLorenzo D; Kabata Y; Shinkuma S; Salas-Alanis JC; Christiano AM
Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26846-26852. PubMed ID: 31818947
[TBL] [Abstract][Full Text] [Related]
2. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.
Izmiryan A; Ganier C; Bovolenta M; Schmitt A; Mavilio F; Hovnanian A
Mol Ther Nucleic Acids; 2018 Sep; 12():554-567. PubMed ID: 30195791
[TBL] [Abstract][Full Text] [Related]
4. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
5. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
[TBL] [Abstract][Full Text] [Related]
7. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
[TBL] [Abstract][Full Text] [Related]
8.
Liemberger B; Bischof J; Ablinger M; Hainzl S; Murauer EM; Lackner N; Ebner P; Kocher T; Nyström A; Wally V; Mayr E; Guttmann-Gruber C; Hofbauer JP; Bauer JW; Koller U
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901775
[TBL] [Abstract][Full Text] [Related]
9. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
[TBL] [Abstract][Full Text] [Related]
10. A non-viral and selection-free
Kocher T; Bischof J; Haas SA; March OP; Liemberger B; Hainzl S; Illmer J; Hoog A; Muigg K; Binder HM; Klausegger A; Strunk D; Bauer JW; Cathomen T; Koller U
Mol Ther Nucleic Acids; 2021 Sep; 25():237-250. PubMed ID: 34458008
[TBL] [Abstract][Full Text] [Related]
11. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by
García M; Bonafont J; Martínez-Palacios J; Xu R; Turchiano G; Svensson S; Thrasher AJ; Larcher F; Del Rio M; Hernández-Alcoceba R; Garín MI; Mencía Á; Murillas R
Mol Ther Methods Clin Dev; 2022 Dec; 27():96-108. PubMed ID: 36212909
[TBL] [Abstract][Full Text] [Related]
12. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
Tolar J; Xia L; Riddle MJ; Lees CJ; Eide CR; McElmurry RT; Titeux M; Osborn MJ; Lund TC; Hovnanian A; Wagner JE; Blazar BR
J Invest Dermatol; 2011 Apr; 131(4):848-56. PubMed ID: 21124339
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa.
Wang X; Wang X; Li Y; A S; Qiu B; Bushmalyova A; He Z; Wang W; Lara-Sáez I
Mol Ther Methods Clin Dev; 2023 Dec; 31():101134. PubMed ID: 38027067
[TBL] [Abstract][Full Text] [Related]
14. Cytosine Deaminase Base Editing to Restore
Naso G; Gkazi SA; Georgiadis C; Jayarajan V; Jacków J; Fleck R; Allison L; Ogunbiyi OK; McGrath JA; Ilic D; Di WL; Petrova A; Qasim W
JID Innov; 2023 May; 3(3):100191. PubMed ID: 37213713
[TBL] [Abstract][Full Text] [Related]
15. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
16. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.
Webber BR; Osborn MJ; McElroy AN; Twaroski K; Lonetree CL; DeFeo AP; Xia L; Eide C; Lees CJ; McElmurry RT; Riddle MJ; Kim CJ; Patel DD; Blazar BR; Tolar J
NPJ Regen Med; 2016; 1():16014-. PubMed ID: 28250968
[TBL] [Abstract][Full Text] [Related]
18. A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa.
Neumayer G; Torkelson JL; Li S; McCarthy K; Zhen HH; Vangipuram M; Jackow J; Rami A; Hansen C; Guo Z; Gaddam S; Pappalardo A; Li L; Cramer A; Roy KR; Nguyen TM; Tanabe K; McGrath PS; Bruckner A; Bilousova G; Roop D; Bailey I; Tang JY; Christiano A; Steinmetz LM; Wernig M; Oro AE
bioRxiv; 2023 Mar; ():. PubMed ID: 36909618
[TBL] [Abstract][Full Text] [Related]
19. Characterization of mutations of the type VII collagen gene (COL7A1) in recessive dystrophic epidermolysis bullosa mitis (M-RDEB) from three Korean patients.
Ryoo YW; Kim BC; Lee KS
J Dermatol Sci; 2001 Jun; 26(2):125-32. PubMed ID: 11378329
[TBL] [Abstract][Full Text] [Related]
20. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Zanta-Boussif MA; Décha A; Pironon N; Tonasso L; Mejia JE; Brice A; Danos O; Hovnanian A
Mol Ther; 2010 Aug; 18(8):1509-18. PubMed ID: 20485266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
